Table 5. Adverse events related to anthracycline/taxane-based, single-agent taxane-based, and platinum-based chemotherapy in combination with pertuzumab and trastuzumab.
| Toxicities | TCbHP (n=65), n (%) | THP (n=35), n (%) | AC-THP (n=37), n (%) | |||||
|---|---|---|---|---|---|---|---|---|
| Any grade | Grade 3–4 | Any grade | Grade 3–4 | Any grade | Grade 3–4 | |||
| Neutropenia | 23 (35.4) | 2 (3.1) | 13 (37.1) | 3 (8.6) | 16 (43.2) | 3 (8.1) | ||
| Anemia | 50 (76.9) | 7 (10.8) | 15 (42.9) | 1 (2.9) | 19 (51.4) | 2 (5.4) | ||
| Thrombocytopenia | 25 (38.5) | 3 (4.6) | 2 (5.7) | 0 (0.0) | 3 (8.1) | 0 (0.0) | ||
| Elevated transaminase | 18 (27.7) | 3 (3.2) | 10 (28.6) | 3 (8.6) | 16 (43.2) | 0 (0.0) | ||
| Nausea and vomiting | 36 (55.4) | 8 (12.3) | 17 (48.6) | 2 (5.7) | 19 (51.4) | 1 (2.7) | ||
| Diarrhea | 14 (21.5) | 0 (0.0) | 7 (20.0) | 0 (0.0) | 11 (29.7) | 1 (2.7) | ||
| Febrile neutropenia | 4 (6.2) | 0 (0.0) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Decrease in cardiac function | 4 (6.2) | 0 (0.0) | 2 (5.7) | 0 (0.0) | 5 (13.5) | 0 (0.0) | ||
| Fatigue | 27 (41.5) | 0 (0.0) | 15 (42.9) | 0 (0.0) | 21 (56.8) | 0 (0.0) | ||
| Hair loss | 28 (43.1) | 0 (0.0) | 12 (34.3) | 0 (0.0) | 18 (48.6) | 0 (0.0) | ||
| Rash | 7 (10.8) | 0 (0.0) | 2 (5.7) | 0 (0.0) | 1 (2.7) | 0 (0.0) | ||
TCbHP, carboplatin plus taxane in combination with pertuzumab and trastuzumab; THP, taxane in combination with trastuzumab and pertuzumab; AC-THP, a sequence of anthracycline plus cyclophosphamide followed by taxane plus pertuzumab and trastuzumab.